Cabergoline Tablets are contraindicated in patients with Uncontrolled hypertension or known hypersensitivity to ergot derivatives.
History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders.(See PRECAUTIONS, Fibrosis).
Valvulopathy: Post marketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.
These cases have generally occurred during long-term administration of high doses of cabergoline (>2mg/day) used for the treatment of Parkinson's disease.
Rare cases have been reported associated with short-term treatment (<6 months) or in patients receiving lower doses for the treatment of hyperprolactinemia.Physicians should use the lowest effective dose of cabergoline for the treatment of hyperprolactinemia and should periodically reassess the need for continuing therapy with cabergoline.
In addition, patients receiving long term treatment with cabergoline should undergo periodic reassessment of their cardiac status, and echocardiography should be considered.Any patient who develops signs or symptoms of cardiac disease, including dyspnea, edema, congestive heart failure, or a new cardiac murmur, while being treated with cabergoline should be evaluated for possible valvulopathy.Cabergoline should be used with caution in patients who have hemodynamically significant valvular disease or have been exposed to other medications associated with valvulopathy.Pregnancy: Dopamine agonists in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia eclampsia, and post partum hypertension, unless the potential benefit is judged to outweigh the possible risk.